Principal Investigators

    PAN, PING-YUE

    Institution

    ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

    Contact information of lead PI

    Country

    USA

    Title of project or programme

    SYNJ1 Mediates a Novel Signaling Pathway in Parkinsons Disease

    Source of funding information

    NIH (NINDS)

    Total sum awarded (Euro)

    427637.6147

    Start date of award

    30/09/2015

    Total duration of award in years

    1

    Keywords

    synaptojanin, LRRK2 gene, Synaptic Vesicles, dopaminergic neuron, Parkinson Disease

    Research Abstract

    ? DESCRIPTION (provided by applicant): The goal of our project is to investigate pathogenic mechanism underlying Parkinson’s disease (PD) based on inherited forms of PD. We and two other groups have identified the same mutation in SYNJ1 gene on chromosome 21q22 that is associated with early onset Parkinsonism. As one of the most important inositol phosphatases in the brain, synaptojanin1 (encoded by SYNJ1) is involved in many aspects of membrane trafficking and has been implicated in a number of brain disorders including Alzheimer’s disease and Down’s syndrome. However, its pathogenic mechanism in PD has not been studied. Emerging evidence reveals the convergence of pathogenic pathways for ?-synuclein, LRRK2 and other PD-related genes in deregulating synaptic vesicle (SV) cycling in the early stage of PD. Our preliminary study shows shared phenotypes in SV endocytosis and dopaminergic transmission in SYNJ1 heterozygous mice and LRRK2-G2019S mice. SYNJ1 heterozygous mice develop abnormal dendritic morphology and lipid composition selectively in substantia nigra. Given that synaptojanin1 forms a protein complex with endophilin A, which was identified as a putative LRRK2 substrate, we propose a “”LRRK2-endophilinA-synaptojanin1″” signaling axis for the regulation of SV cycling, which is deregulated in PD. We will test the hypothesis using state-of-art optical tools and genetic animal models. Completion of our project is expected to provide insight into the pathogenic mechanism for PD and open new avenues for identification of novel therapeutics.

    Further information available at:

Types: Investments < €500k
Member States: United States of America
Diseases: N/A
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF